Abstract: Objective To observe the therapeutic effect and safety of vildagliptin combined with insulin aspart injection in
elderly patients with type 2 diabetes. Methods Sixty-six elderly patients with type 2 diabetes who had poor blood glucose
control with insulin aspart injection were divided into two groups to have additional Vildagliptin (50mg, twice daily, n=36,
observation group) or Acarbose (50 mg, three times a day, n=30, control group). Blood glucose (including FBG and 2hPG),
HbA1C, fasting c-peptide, postprandial c-peptide, BMI and GFR were observed after 12 weeks. Results In the observation
group, FBG, 2hPG and HbA1C decreased significantly (P<0.05), fasting and postprandial c-peptide increased (P<0.05), and
BMI and GFR showed no obvious changes (P>0.05). In the control group, 2hPG and HbA1C were significant lowered (P<0.05)
but FBG, fasting and postprandial c-peptide, BMI or GFR showed no changes (P>0.05). Compared with those in the control
group, FBG in the observation group showed a significant reduction (P<0.05), but no significant differences were found in
2hPG, HbA1C, BMI or GFR (P>0.05). No hypoglycemia occurred in the two groups during the treatment. Conclusion
Vildagliptin with insulin aapart injection has equivalent effect with Acarbose combined with insulin aspart injection in
decreasing 2hPG and HbA1C without increasing the body weight or the risk to hypoglycemia or causing lowered GFR.
Vildagliptin has better effect in decreasing FBG and improving the function of the islet cells.